JNJ Stock: A $100 Billion Milestone — But Is the Fortress Fully Priced?

Johnson & Johnson (JNJ) Q2 2026 — Johnson & Johnson (JNJ) reported a clean Q2 2026 beat: sales +6.6% to $25.3B, adjusted EPS $2.90 (+4.7%, ahead of estimates), with Innovative Medicine (pharma) sales +6.8% out-growing the patent cliffs. It RAISED full-year guidance to ~$101.1B sales (+7.3%) and $11.68 adjusted EPS (+8.2%) — on track to cross $100B in annual revenue for the first time in its 140-year history. The AAA-rated Dividend King (~250) has recovered strongly off its ~$162 low to ~7% below its ~$269 high, and rose on the print. Johnson & Johnson is the ultimate healthcare fortress — a diversified, AAA-rated giant (one of only a handful on earth) with two engines (Innovative Medicine pharma + MedTech devices) and a 60+ year dividend-increase streak. In Q2 2026 it beat (sales +6.6% to $25.3B, adjusted EPS $2.90) and RAISED guidance to ~$101.1B sales and $11.68 adjusted EPS — crossing $100B in annual revenue for the first time in 140 years. The pharma engine (+6.8%) is out-growing the Stelara-style patent cliffs, which is the whole long-term debate. The overhangs are talc litigation and drug-pricing policy, and after recovering near its highs it trades at ~21x forward for ~8% growth — full, not cheap. Our owner-earnings work lands near $260 (vs ~$250), below the Street's ~$272. Our call: HOLD, 3/5 — a beat-and-raise from a fortress at a fair price; own it for resilience and the ~3% AAA-backed dividend, add on talc-driven dips. Not financial advice. THE CALL: HOLD (3/5, A HEALTHCARE FORTRESS, BEAT AND RAISED, AT A FAIR PRICE) — base-case value ~$260 vs ~$250 today. What to watch: a clean, capped talc-litigation settlement (removing the biggest overhang), continued pharma-pipeline launches out-growing the Stelara patent cliff, and talc-headline dips toward the low $230s as add points Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.